Anzeige
Meldung des Tages: Gold auf 6.300 USD? Diese Aktie könnte der geheime Hebel sein

Tiziana Life Sciences ADR News

Aktie
WKN:  A2PTNF ISIN:  US88875G1013
Keine aktuellen Kursdaten verfügbar
Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.
Marktkapitalisierung *
-
Streubesitz
-
KGV
-
Index-Zuordnung
-

Tiziana Life Sciences ADR News

14.04.26 - GlobeNewswire
Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress
BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, ...
01.04.26 - GlobeNewswire
Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging
BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:  TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal ...
25.02.26 - GlobeNewswire
Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA
BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:  TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal ...
20.01.26 - GlobeNewswire
Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab
BOSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, ...
16.01.26 - GlobeNewswire
Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares
BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:  TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal ...
16.01.26 - GlobeNewswire
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million
BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, ...
09.01.26 - GlobeNewswire
Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco
BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:  TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal ...
29.12.25 - GlobeNewswire
Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA
Tiziana reports excellent safety profile with intranasal foralumab after 37.4 patient-​years cumulative exposure FDA denial of Sanofi’s tolebrutinib for nrSPMS shows need for safe ...
19.12.25 - GlobeNewswire
Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman
BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:  TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough ...
17.12.25 - GlobeNewswire
Tiziana Life Sciences to Ring the Closing Bell at Nasdaq
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:  TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough ...
17.12.25 - GlobeNewswire
Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial
First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-​Controlled Phase 2 Trial Builds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s Patients ...
15.12.25 - GlobeNewswire
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough ...
15.12.25 - GlobeNewswire
Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough ...
12.12.25 - GlobeNewswire
Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial
First Patient Expected to be Dosed Next Week with Intranasal Foralumab PET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer’s Patient on Leqembi ® ...
02.12.25 - GlobeNewswire
Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company
BOSTON, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:  TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough ...
25.11.25 - GlobeNewswire
Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program
BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough ...
13.11.25 - GlobeNewswire
Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference
BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough ...
29.10.25 - GlobeNewswire
Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy
BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough ...
30.09.25 - GlobeNewswire
Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia
BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough ...
25.09.25 - GlobeNewswire
Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody
BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), today announces it will advance its second asset, a fully ...

Newssuche

Videos

newspaper
07.04.26 +1,32%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »